| 000 | 01123 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515165427.0 | ||
| 264 | 0 | _c20090608 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a1535-7163 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-09-0042 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKirkland, James B | |
| 245 | 0 | 0 |
_aNiacin status and treatment-related leukemogenesis. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _cApr 2009 |
||
| 300 |
_a725-32 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBone Marrow Cells _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia _xetiology |
| 650 | 0 | 4 |
_aNiacin _xadministration & dosage |
| 650 | 0 | 4 | _aNutritional Status |
| 650 | 0 | 4 |
_aPoly Adenosine Diphosphate Ribose _xmetabolism |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 8 _gno. 4 _gp. 725-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-09-0042 _zAvailable from publisher's website |
| 999 |
_c18804324 _d18804324 |
||